For NPC patients infected with SARS-CoV-2, EBV DNA alone is insufficient for monitoring relapse after radical therapy. Long-term follow-up and underlying mechanistic investigations of EBV DNA changes are urgently needed.
Keyphrases
- epstein barr virus
- end stage renal disease
- sars cov
- diffuse large b cell lymphoma
- ejection fraction
- chronic kidney disease
- newly diagnosed
- circulating tumor
- cell free
- single molecule
- peritoneal dialysis
- prognostic factors
- respiratory syndrome coronavirus
- coronavirus disease
- nucleic acid
- smoking cessation
- free survival